Intrathecal baclofen for dystonia: Benefits and complications during six years of experience

Walker, Ruth H.; Danisi, Fabio; Swope, David; Goodman, Robert; Germano, Isabelle M.; Brin, Mitchell F.

doi:10.1002/1531-8257(200011)15:6<1242::aid-mds1028>3.0.co;2-z

Cited by 109 publications

(39 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most forms of dystonia respond poorly to systemic medications and intrathecal baclofen. 18,51 Botulinum toxin-induced denervation is helpful for focal dystonias, but its efficacy may wane over time, and additionally it is impractical in more generalized cases. Recently, chronic electrical stimulation of the GP has shown benefit for dystonia in a few case series.…”

mentioning

confidence: 99%

Microelectrode-guided implantation of deep brain stimulators into the globus pallidus internus for dystonia: techniques, electrode locations, and outcomes

Starr

Turner

Rau

et al. 2006

JNS

239

215

View full text Add to dashboard Cite

Physiologically guided implantation of DBS electrodes in patients with dystonia was technically feasible in the awake state in most patients, and the morbidity rate was low. Spontaneous discharge rates of GPI neurons in dystonia were similar to those of globus pallidus externus neurons, such that the two nuclei must be distinguished by neuronal discharge patterns rather than rates. Active electrode locations associated with robust improvement (> 70% decrease in BFMDRS score) were located near the intercommissural plane, at a mean distance from the pallidocapsular border of 3.6 mm.

show abstract

mentioning

confidence: 99%

Microelectrode-guided implantation of deep brain stimulators into the globus pallidus internus for dystonia: techniques, electrode locations, and outcomes

Starr

Turner

Rau

et al. 2006

JNS

239

215

View full text Add to dashboard Cite

show abstract

“…-liées au matériel (fracture de cathéter, infection) ; -possible aggravation de la symptomatologie ; -dyskinésies, hypotonie ; -léthargie et même suicide dans certaines séries [10].…”

Section: Discussionunclassified

Paraplégies spastiques héréditaires et troubles vésico-sphinctériens

et al. 2006

View full text Add to dashboard Cite

Les troubles vésicosphinctériens dans la paraplégie spastique héréditaire sont fréquents. Nous rapportons trois cas permettant de discuter de prise en charge récente de l'hyperactivité vésicale par anticholinergiques, électromodulation des racines sacrées et injections de toxine botulique et de la dyssynergie vésicosphinctérienne.Mots clés : Paraplégie spastique héréditaire -Vessie neurologique -Anticholinergiques Vesico-sphincteric disorders in hereditary spastic paraplegiaAbstract: Bladder sphincter disorders in hereditary spastic paraplegia occur frequently. Here, we report three cases involving the treatment of neurogenic bladder overactivity with anticholinergics, sacral neuromodulation and botulinum toxin injections. We also discuss detrusor sphincter dyssynergia.

show abstract

“…13 Intrathecal baclofen can be helpful in selected populations. 6,14 Interest in deep brain stimulation in particular has been growing, and it is the focus of another review in this issue.…”

Section: Current Treatment Optionsmentioning

confidence: 99%

Experimental Therapeutics for Dystonia

Jinnah

Hess

2008

Neurotherapeutics

View full text Add to dashboard Cite

Summary: Dystonia is a neurological syndrome characterized by excessive involuntary muscle contractions leading to twisting movements and unnatural postures. It has many different clinical manifestations, and many different causes. More than 3 million people worldwide suffer from dystonia, yet there are few broadly effective treatments. In the past decade, progress in research has advanced our understanding of the pathogenesis of dystonia to a point where drug discovery efforts are now feasible. Several strategies can be used to develop novel therapeutics for dystonia. Existing therapies have only modest efficacy, but may be refined and improved to increase benefits while reducing side effects. Identifying rational targets for drug intervention based on the pathogenesis of dystonia is another strategy. The surge in both basic and clinical research discoveries has provided insights at all levels, including etiological, physiological and nosological, to enable such a targeted approach. The empirical approach to drug discovery, whereby compounds are identified using a nonmechanistic strategy, is complementary to the rational approach. With the recent development of multiple animal models of dystonia, it is now possible to develop assays and perform drug screens on vast numbers of compounds. This multifaceted approach to drug discovery in dystonia will likely provide lead compounds that can then be translated for clinical use.

show abstract

Intrathecal baclofen for dystonia: Benefits and complications during six years of experience

Cited by 109 publications

References 48 publications

Microelectrode-guided implantation of deep brain stimulators into the globus pallidus internus for dystonia: techniques, electrode locations, and outcomes

Microelectrode-guided implantation of deep brain stimulators into the globus pallidus internus for dystonia: techniques, electrode locations, and outcomes

Paraplégies spastiques héréditaires et troubles vésico-sphinctériens

Experimental Therapeutics for Dystonia

Contact Info

Product

Resources

About